NurExone Biologic Inc.: NurExone Reports Second Quarter 2022

NurExone Biologic Inc.: NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update


Calgary, Alberta--(Newsfile Corp. - August 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided

Related Keywords

New York , United States , Canada , United Kingdom , Toronto , Ontario , Israel , Singapore , Vancouver , British Columbia , Canadian , James Jay Richardson , Canaccord Genuity , Lior Shaltiel , Oded Orgil , Jay Richardson , Clarkson Gordon Arthur Young , Advisory Services , Twitter , Enerspar Corp The Company Or Nurexone , Polyrizon Ltd , Royal Canadian Academy Mr , Canada Israel Chamber , Insolvency Practitioner Association Of The United Kingdom , Nurexone Biologic Inc , Facebook , York University , Alberta Newsfile Corp , Venture Exchange , Medigus Ltd , Merrill Lynch , Targus Corporation , Drug Administration , University Of Western Ontario , Adcore Inc , Technion University , Youtube , Ernst Young , Israel Institute Of Technology , Manulife Financial , Research Agreement , Exone Biologic , Enerspar Corp , Chemistry Manufacturing , Pre Investigational New Drug , Intellectual Property , Spinal Cord Injury , Reverse Takeover Transaction , Extracellular Vesicles , Central Nervous System , Patent Cooperation Treaty , Sponsor Research Agreement , Collaboration Agreement , Canadian Chartered Accountant , Singapore Certified Public Accountant , Insolvency Practitioner Association , Interim Chairman , Royal Canadian Academy , Capital Markets , Financial Advisor , Senior Executive , Gravitas Securities , San Jose , Bay Street , Western Ontario , Political Science , Quarter Fiscal , Services Shares , Israel Institute , Executive Officer , Nurexone , Biologic , Reports , Second , Quarter , 022 , Financial , Results , Rovides , Business , Update ,

© 2025 Vimarsana